文献速递心脑血管急症

薄复合丝耐用聚合物涂层支架(Resolute Onyx)与超薄钴铬合金丝生物可吸收聚合物涂层支架(Orsiro)在冠心病全人群中的比较(BIONYX):国际单盲随机非劣效性试验

Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial.
PubMed 文献 · Lancet · 2018-09-22
一句话结论在冠心病全人群中,Resolute Onyx支架1年靶血管失败率非劣效于Orsiro支架(4.5% vs 4.7%,绝对风险差-0.2%),且确定或可能的支架血栓发生率更低(0.1% vs 0.7%)。

BIONYX是一项研究者发起、评估者与患者单盲、随机非劣效性试验,在比利时、以色列和荷兰7个独立监查中心纳入2516例需行药物洗脱支架经皮冠状动脉介入治疗的18岁及以上全人群患者,随机1:1分配至Resolute Onyx组或Orsiro组,按性别和糖尿病状态分层。主要终点为1年靶血管失败(心源性死亡、靶血管相关心肌梗死和靶血管血运重建的复合终点),非劣效界值2.5%。意向性治疗分析纳入2488例(Resolute Onyx组1243例,Orsiro组1245例),70.9%表现为急性冠脉综合征,51.2%有心肌梗死。1年随访率99.6%。主要终点Resolute Onyx组55例(4.5%)vs Orsiro组58例(4.7%),绝对风险差-0.2%(95%CI -1.9至1.4),单侧95%CI上限1.1%,非劣效性成立(p=0.0005)。确定或可能的支架血栓Resolute Onyx组1例(0.1%)vs Orsiro组9例(0.7%),风险比0.11(95%CI 0.01-0.87),p=0.0112。作者认为Resolute Onyx支架在1年复合安全性和有效性终点上非劣效于Orsiro支架,两组事件率均低提示两种支架均安全,Resolute Onyx组极低的支架血栓率需进一步临床研究。

要点

  • 在冠心病全人群(70.9%急性冠脉综合征,51.2%心肌梗死)中,Resolute Onyx支架1年靶血管失败率4.5% vs Orsiro 4.7%,绝对风险差-0.2%(95%CI -1.9至1.4),非劣效性成立(p=0.0005)。
  • 确定或可能的支架血栓发生率Resolute Onyx组0.1%(1例)vs Orsiro组0.7%(9例),风险比0.11(95%CI 0.01-0.87),p=0.0112。
  • 两组1年随访率99.6%(2478/2488),主要终点事件率均低(Resolute Onyx 4.5%,Orsiro 4.7%)。
  • 作者认为两种支架均安全,Resolute Onyx组极低的支架血栓率需进一步临床研究。

适用人群与场景

  • 纳入标准:年龄18岁及以上、需要经皮冠状动脉介入治疗并置入药物洗脱支架的全人群患者。
  • 场景:在比利时、以色列和荷兰7个独立监查中心行经皮冠状动脉介入治疗。
  • 病情阶段:70.9%表现为急性冠脉综合征,51.2%有心肌梗死。

诊断标准与关键阈值

  • 主要终点:1年靶血管失败,为心源性死亡、靶血管相关心肌梗死和靶血管血运重建的复合终点,由独立事件委员会裁定,按意向性治疗分析。
  • 非劣效界值:2.5%。

处置流程与药物剂量

  • 导丝通过后伴或不伴预扩张,导管室团队成员使用基于网络的计算机生成分配序列将患者1:1随机分配至Resolute Onyx支架或Orsiro支架,按性别和糖尿病状态分层。
  • 患者和评估者设盲,治疗临床医生不设盲。

研究设计与关键结果

  • 研究设计:研究者发起、评估者与患者单盲、随机非劣效性试验,在比利时、以色列和荷兰7个独立监查中心纳入2516例患者,随机1:1分配至Resolute Onyx组或Orsiro组。
  • 意向性治疗分析纳入2488例(Resolute Onyx组1243例,Orsiro组1245例),28例退出或筛查失败;1年随访率99.6%(2478/2488)。
  • 主要终点:Resolute Onyx组55例(4.5%)vs Orsiro组58例(4.7%),绝对风险差-0.2%(95%CI -1.9至1.4),单侧95%CI上限1.1%,非劣效性p=0.0005。
  • 确定或可能的支架血栓:Resolute Onyx组1例(0.1%)vs Orsiro组9例(0.7%),风险比0.11(95%CI 0.01-0.87),p=0.0112。

证据类型、等级与局限

  • 证据类型:国际、单盲、随机非劣效性试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在需行经皮冠状动脉介入治疗的冠心病全人群中,Resolute Onyx支架1年靶血管失败率非劣效于Orsiro支架。
  • 确定或可能的支架血栓发生率Resolute Onyx组低于Orsiro组(0.1% vs 0.7%,风险比0.11,95%CI 0.01-0.87)。
  • 作者认为两种支架均安全,Resolute Onyx组极低的支架血栓率需进一步临床研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: During the past decade, many patients had zotarolimus-eluting stents implanted, which had circular shape cobalt-chromium struts with limited radiographic visibility. The Resolute Onyx stent was developed to improve visibility while reducing strut thickness, which was achieved by using a novel composite wire with a dense platinum-iridium core and an outer cobalt-chromium layer. We did the first randomised clinical trial to assess the safety and efficacy of this often-used stent compared with the Orsiro stent, which consists of ultrathin cobalt-chromium struts.

METHODS: We did an investigator-initiated, assessor-blinded and patient-blinded, randomised non-inferiority trial in an allcomers population at seven independently monitored centres in Belgium, Israel, and the Netherlands. Eligible participants were aged 18 years or older and required percutaneous coronary intervention with drug-eluting stents. After guide wire passage with or without predilation, members of the catheterisation laboratory team used web-based computer-generated allocation sequences to randomly assign patients (1:1) to either the Resolute Onyx or the Orsiro stent. Randomisation was stratified by sex and diabetes status. Patients and assessors were masked to allocated stents, but treating clinicians were not. The primary endpoint was target vessel failure at 1 year, a composite of cardiac death, target-vessel-related myocardial infarction, and target vessel revascularisation, and was assessed by intention to treat (non-inferiority margin 2·5%) on the basis of outcomes adjudicated by an independent event committee. This trial is registered with ClinicalTrials.gov, number NCT02508714.

FINDINGS: Between Oct 7, 2015, and Dec 23, 2016, 2516 patients were enrolled, 2488 of whom were included in the intention-to-treat analysis (28 withdrawals or screening failures). 1243 participants were assigned to the Resolute Onyx group, and 1245 to the Orsiro group. Overall, 1765 (70·9%) participants presented with acute coronary syndromes and 1275 (51·2%) had myocardial infarctions. 1-year follow-up was available for 2478 (99·6%) patients. The primary endpoint was met by 55 (4·5%) patients in the Resolute Onyx group and 58 (4·7%) in the Orsiro group. Non-inferiority of Resolute Onyx to Orsiro was thus established (absolute risk difference -0·2% [95% CI -1·9 to 1·4]; upper limit of the one-sided 95% CI 1·1%; pnon-inferiority=0·0005). Definite or probable stent thrombosis occurred in one (0·1%) participant in the Resolute Onyx group and nine (0·7%) in the Orsiro group (hazard ratio 0·11 [95% CI 0·01-0·87]; p=0·0112).

INTERPRETATION: The Resolute Onyx stent was non-inferior to Orsiro for a combined safety and efficacy endpoint at 1-year follow-up in allcomers. The low event rate in both groups suggests that both stents are safe, and the very low rate of stent thrombosis in the Resolute Onyx group warrants further clinical investigation.

FUNDING: Biotronik and Medtronic.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. von Birgelen C, Zocca P, Buiten RA, et al. Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. Lancet. 2018. PMID: 30253879. doi:10.1016/S0140-6736(18)32001-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。